Antibody Technologies

Sep 2024

Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective

2.050,00€

Oct 2023

EpCAM-Targeted Antibodies Pipeline Review

200,00€

Aug 2023

Claudin 18.2-Targeted Immunotherapy: a landscape analysis of stakeholders, drug modalities, pipeline and business opportunities from an industry perspective

2.150,00€

Feb 2023

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

1.600,00€

Jul 2022

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

2.550,00€

1.800,00€

Jul 2022

GPRC5D-Targeted Therapy: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

600,00€

May 2022

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

500,00€

Oct 2021

2FOR1 Report Package: Vectorized Antibody and Prodrug Antibody & Cytokine landscape analysis report package with 50% discount

4.400,00€

2.200,00€

Oct 2021

Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

2.250,00€

Jul 2021

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective

2.150,00€

Report categories

Antibody & Protein Sales

Antibody Technologies

Biosimilar Antibodies & Proteins

Drug the Undruggable Technologies

Immuno-Oncology

mRNA Vaccines & Therapeutics

NK Cells & CAR Macrophages

Pipeline Database

RNA-Targeted Therapeutics

Target Pipelines

TCR T-Cells and Antibodies

Therapeutic Antibodies

Therapeutic Proteins & Peptides